AU2018218179B2 - Methods of treating influenza - Google Patents

Methods of treating influenza Download PDF

Info

Publication number
AU2018218179B2
AU2018218179B2 AU2018218179A AU2018218179A AU2018218179B2 AU 2018218179 B2 AU2018218179 B2 AU 2018218179B2 AU 2018218179 A AU2018218179 A AU 2018218179A AU 2018218179 A AU2018218179 A AU 2018218179A AU 2018218179 B2 AU2018218179 B2 AU 2018218179B2
Authority
AU
Australia
Prior art keywords
influenza
virus
influenza virus
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018218179A
Other languages
English (en)
Other versions
AU2018218179A1 (en
Inventor
Gary Ewart
Carolyn Luscombe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotron Ltd
Original Assignee
Biotron Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017900385A external-priority patent/AU2017900385A0/en
Application filed by Biotron Ltd filed Critical Biotron Ltd
Publication of AU2018218179A1 publication Critical patent/AU2018218179A1/en
Application granted granted Critical
Publication of AU2018218179B2 publication Critical patent/AU2018218179B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2018218179A 2017-02-08 2018-02-07 Methods of treating influenza Active AU2018218179B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017900385 2017-02-08
AU2017900385A AU2017900385A0 (en) 2017-02-08 Methods of treating influenza
PCT/AU2018/050085 WO2018145148A1 (en) 2017-02-08 2018-02-07 Methods of treating influenza

Publications (2)

Publication Number Publication Date
AU2018218179A1 AU2018218179A1 (en) 2019-08-22
AU2018218179B2 true AU2018218179B2 (en) 2023-05-04

Family

ID=63106827

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018218179A Active AU2018218179B2 (en) 2017-02-08 2018-02-07 Methods of treating influenza

Country Status (12)

Country Link
US (1) US10918623B2 (enExample)
EP (1) EP3579833B1 (enExample)
JP (1) JP7019727B2 (enExample)
KR (1) KR102607599B1 (enExample)
CN (1) CN110325187B (enExample)
AU (1) AU2018218179B2 (enExample)
BR (1) BR112019016316A2 (enExample)
ES (1) ES2910136T3 (enExample)
MX (1) MX387115B (enExample)
RU (1) RU2769317C2 (enExample)
SG (1) SG11201907034PA (enExample)
WO (1) WO2018145148A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2524356T3 (es) 2010-07-22 2014-12-05 Gilead Sciences, Inc. Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
TWI687432B (zh) 2014-10-29 2020-03-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
DK3785717T3 (da) 2015-09-16 2022-03-21 Gilead Sciences Inc Fremgangsmåder til behandling af coronaviridae-infektioner
US10682368B2 (en) 2017-03-14 2020-06-16 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
CA3059777C (en) 2017-05-01 2023-02-21 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
JP2023512656A (ja) 2020-01-27 2023-03-28 ギリアード サイエンシーズ， インコーポレイテッド ＳＡＲＳ ＣｏＶ－２感染を治療するための方法
KR20220153619A (ko) 2020-03-12 2022-11-18 길리애드 사이언시즈, 인코포레이티드 1'-시아노 뉴클레오사이드의 제조 방법
CA3172483A1 (en) 2020-04-06 2021-10-14 Scott Ellis Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
TW202203941A (zh) 2020-05-29 2022-02-01 美商基利科學股份有限公司 瑞德西韋之治療方法
PE20230618A1 (es) 2020-06-24 2023-04-14 Gilead Sciences Inc Analogos de nucleosido de 1'-ciano y usos de los mismos
IL300412A (en) 2020-08-24 2023-04-01 Gilead Sciences Inc Phospholipid compounds and their uses
IL300453A (en) 2020-08-27 2023-04-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
TW202344257A (zh) 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
WO2022251318A1 (en) 2021-05-26 2022-12-01 Gilead Sciences, Inc. Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
JP2024543259A (ja) * 2021-11-24 2024-11-20 バイオトロン リミティッド ＳＡＲＳ－ＣｏＶ－２感染を治療する方法
KR20240154646A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
JP2025508941A (ja) 2022-03-03 2025-04-10 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス化合物並びにその作製及び使用方法
KR20240155326A (ko) 2022-03-03 2024-10-28 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물 및 이의 제조와 사용 방법
US20240009220A1 (en) 2022-06-06 2024-01-11 Gilead Sciences, Inc. Methods for treatment of viral infections
WO2024006376A1 (en) 2022-06-29 2024-01-04 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
EP4547665A1 (en) 2022-06-30 2025-05-07 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
WO2024173458A1 (en) 2023-02-16 2024-08-22 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
US20250090537A1 (en) 2023-08-31 2025-03-20 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
AU2024330988A1 (en) 2023-08-31 2026-02-19 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
WO2025054278A1 (en) 2023-09-06 2025-03-13 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US20250109157A1 (en) 2023-09-28 2025-04-03 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140066487A1 (en) * 2005-06-24 2014-03-06 Biotron Limited Antiviral compounds and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100254942A1 (en) * 2007-08-03 2010-10-07 Biotron Limited Hepatitis c antiviral compositions and methods
KR101369584B1 (ko) * 2011-04-19 2014-03-06 일양약품주식회사 페닐-이속사졸 유도체 및 그의 제조방법
AU2015287994B2 (en) * 2014-07-07 2020-03-12 Prophylaxis, Llc Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
CN110870864B (zh) 2018-08-29 2021-09-24 复旦大学 马来酸卡比沙明在制备抗流感病毒药物中的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140066487A1 (en) * 2005-06-24 2014-03-06 Biotron Limited Antiviral compounds and methods
US20160376231A1 (en) * 2005-06-24 2016-12-29 Biotron Limited Antiviral compounds and methods

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Jalily et al., "Mechanisms of Action of Novel Influenza A/M2 Viroporin Inhibitors Derived from Hexamethylene Amiloride," Molecular Pharmacology, 2016, vol. 90, pages 80-95. *
Nieva et al., "Viroporins: structure and biological functions", Nature Reviews Microbiology, 2012, vol. 10, pages 563 - 574. *
Wilkinson et al., "A Phase 1b/2a study of the safety, pharmacokinetics and antiviral activity of BIT225 in patients with HIV-1 infection," 2016, J Antimicrobial Chemotherapy, 2016, vol. 71, pages 731-738 *

Also Published As

Publication number Publication date
SG11201907034PA (en) 2019-08-27
WO2018145148A1 (en) 2018-08-16
KR102607599B1 (ko) 2023-11-28
NZ755900A (en) 2025-03-28
US20200093796A1 (en) 2020-03-26
ES2910136T3 (es) 2022-05-11
EP3579833B1 (en) 2022-01-05
RU2769317C2 (ru) 2022-03-30
CN110325187B (zh) 2022-09-30
CN110325187A (zh) 2019-10-11
MX387115B (es) 2025-03-19
MX2019009443A (es) 2019-12-16
EP3579833A1 (en) 2019-12-18
JP2020506243A (ja) 2020-02-27
RU2019126746A3 (enExample) 2021-05-28
KR20190112051A (ko) 2019-10-02
US10918623B2 (en) 2021-02-16
AU2018218179A1 (en) 2019-08-22
JP7019727B2 (ja) 2022-02-15
EP3579833A4 (en) 2021-01-13
BR112019016316A2 (pt) 2020-03-31
CA3052503A1 (en) 2018-08-16
RU2019126746A (ru) 2021-03-09

Similar Documents

Publication Publication Date Title
AU2018218179B2 (en) Methods of treating influenza
Tarbet et al. Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice
Wang et al. Inhibition of the infectivity and inflammatory response of influenza virus by Arbidol hydrochloride in vitro and in vivo (mice and ferret)
WO2017223231A1 (en) (s)-8-(benzhydryl )-6-isopropyl-3,5-dioxo- 5, 6,7,8,-tetrahydro-3h-pyrazino-[1,2-b]pyridazin-yl-isobutyrate antiviral agent for use in treating influenza
Hussein et al. Identification of entry inhibitors with 4-aminopiperidine scaffold targeting group 1 influenza A virus
WO2020241759A1 (ja) インフルエンザウイルス感染症またはコロナウイルス感染症の予防および／または治療剤
Zhang et al. Discovery of cyperenoic acid as a potent and novel entry inhibitor of influenza A virus
US10221152B2 (en) Usage of mycophenolate mofetil or salt thereof in preparing drug for resisting against influenza virus
EP3934653B1 (en) Azelastine as antiviral treatment
CA3052503C (en) Methods of treating influenza
CN110870864B (zh) 马来酸卡比沙明在制备抗流感病毒药物中的应用
HK40017310A (en) Methods of treating influenza
HK40017310B (en) Methods of treating influenza
CN118574614A (zh) 治疗sars-cov-2感染的方法
CN114377009A (zh) Sb216763在制备抗流感病毒药物中的应用
WO2019089734A1 (en) Methods and compositions for the treatment of influenza
Pakvis Current trends of hemagglutinin and M2 protein inhibition for the treatment of influenza using antivirals
CN107898783A (zh) 1，3‑二羟基‑6‑苯并[c]色烯酮在制备抗流感病毒药物中的应用
Wu et al. Pterostilbene inhibits influenza virus infection through interaction with NS1 protein
TWI530284B (zh) 馬替麥考酚酯或其鹽類用於製備抗流感病毒之藥物的用途
Naesens et al. Structure–Activity Relationship of a Novel Class of Aglycoristocetin Derivatives with Potent and Broad Activity Against Influenza Viruses: 61

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)